BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 19007764)

  • 1. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids.
    Skarydová L; Zivná L; Xiong G; Maser E; Wsól V
    Chem Biol Interact; 2009 Mar; 178(1-3):138-44. PubMed ID: 19007764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate.
    Lin HK; Steckelbroeck S; Fung KM; Jones AN; Penning TM
    Steroids; 2004 Dec; 69(13-14):795-801. PubMed ID: 15582534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma.
    Fung KM; Samara EN; Wong C; Metwalli A; Krlin R; Bane B; Liu CZ; Yang JT; Pitha JV; Culkin DJ; Kropp BP; Penning TM; Lin HK
    Endocr Relat Cancer; 2006 Mar; 13(1):169-80. PubMed ID: 16601286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors.
    Penning TM; Steckelbroeck S; Bauman DR; Miller MW; Jin Y; Peehl DM; Fung KM; Lin HK
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):182-91. PubMed ID: 16417966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.
    Gobec S; Brozic P; Rizner TL
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5170-5. PubMed ID: 16183274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3.
    Novotna R; Wsol V; Xiong G; Maser E
    Toxicol Lett; 2008 Sep; 181(1):1-6. PubMed ID: 18616992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3.
    Beranič N; Gobec S; Rižner TL
    Chem Biol Interact; 2011 May; 191(1-3):227-33. PubMed ID: 21182831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis.
    Endo S; Matsunaga T; Kanamori A; Otsuji Y; Nagai H; Sundaram K; El-Kabbani O; Toyooka N; Ohta S; Hara A
    J Nat Prod; 2012 Apr; 75(4):716-21. PubMed ID: 22506594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3).
    Gazvoda M; Beranič N; Turk S; Burja B; Kočevar M; Rižner TL; Gobec S; Polanc S
    Eur J Med Chem; 2013 Apr; 62():89-97. PubMed ID: 23353746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer.
    Rizner TL; Smuc T; Rupreht R; Sinkovec J; Penning TM
    Mol Cell Endocrinol; 2006 Mar; 248(1-2):126-35. PubMed ID: 16338060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs.
    Byrns MC; Penning TM
    Chem Biol Interact; 2009 Mar; 178(1-3):221-7. PubMed ID: 19010312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
    Byrns MC; Steckelbroeck S; Penning TM
    Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity.
    Matsuura K; Shiraishi H; Hara A; Sato K; Deyashiki Y; Ninomiya M; Sakai S
    J Biochem; 1998 Nov; 124(5):940-6. PubMed ID: 9792917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl}propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor.
    Watanabe K; Kakefuda A; Yasuda M; Enjo K; Kikuchi A; Furutani T; Naritomi Y; Otsuka Y; Okada M; Ohta M
    Bioorg Med Chem; 2013 Sep; 21(17):5261-70. PubMed ID: 23845281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.
    Adeniji AO; Twenter BM; Byrns MC; Jin Y; Chen M; Winkler JD; Penning TM
    J Med Chem; 2012 Mar; 55(5):2311-23. PubMed ID: 22263837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.
    Stefane B; Brozic P; Vehovc M; Rizner TL; Gobec S
    Eur J Med Chem; 2009 Jun; 44(6):2563-71. PubMed ID: 19237229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
    Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
    J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening baccharin analogs as selective inhibitors against type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).
    Zang T; Verma K; Chen M; Jin Y; Trippier PC; Penning TM
    Chem Biol Interact; 2015 Jun; 234():339-48. PubMed ID: 25555457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights.
    Byrns MC; Jin Y; Penning TM
    J Steroid Biochem Mol Biol; 2011 May; 125(1-2):95-104. PubMed ID: 21087665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3.
    Hofman J; Malcekova B; Skarka A; Novotna E; Wsol V
    Toxicol Appl Pharmacol; 2014 Aug; 278(3):238-48. PubMed ID: 24832494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.